Published in Am J Psychiatry on June 01, 1998
Brain Circuits in Schizophrenia and Smoking | NCT01369966
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia | NCT03323437
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull (2009) 3.82
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A (2000) 3.34
A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci (2011) 3.23
Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A (2002) 3.11
Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry (2007) 2.98
Linking nucleus accumbens dopamine and blood oxygenation. Psychopharmacology (Berl) (2007) 2.65
A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry (2001) 2.58
The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia. Stereotact Funct Neurosurg (2009) 2.24
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) (2004) 2.06
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull (2010) 1.98
Probabilistic reversal learning impairments in schizophrenia: further evidence of orbitofrontal dysfunction. Schizophr Res (2007) 1.98
A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron (2010) 1.96
The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res (2008) 1.84
Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology (2011) 1.78
Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia. Biol Psychiatry (2013) 1.68
Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr Bull (2008) 1.59
Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des (2009) 1.51
The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) (2003) 1.49
Executive function, neural circuitry, and genetic mechanisms in schizophrenia. Neuropsychopharmacology (2010) 1.47
A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet (2007) 1.43
Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci (2004) 1.39
Gene-environment interplay between cannabis and psychosis. Schizophr Bull (2008) 1.34
Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl (2007) 1.31
The dopaminergic basis of human behaviors: A review of molecular imaging studies. Neurosci Biobehav Rev (2009) 1.30
Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull (2012) 1.22
Altered probabilistic learning and response biases in schizophrenia: behavioral evidence and neurocomputational modeling. Neuropsychology (2011) 1.21
Are we studying and treating schizophrenia correctly? Schizophr Res (2011) 1.19
Impaired timing precision produced by striatal D2 receptor overexpression is mediated by cognitive and motivational deficits. Behav Neurosci (2009) 1.14
Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem (2010) 1.14
Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol (2015) 1.14
Probabilistic learning and inference in schizophrenia. Schizophr Res (2011) 1.12
Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging (2014) 1.11
Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr Bull (2009) 1.10
Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology (Berl) (2005) 1.07
Revitalizing psychiatric therapeutics. Neuropsychopharmacology (2014) 1.05
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry (2013) 1.05
Anterior hippocampal and orbitofrontal cortical structural brain abnormalities in association with cognitive deficits in schizophrenia. Schizophr Res (2009) 1.04
Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation. Psychopharmacology (Berl) (2003) 1.03
Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J Psychiatry Neurosci (2010) 1.03
Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl) (2009) 1.01
Schizophrenia: do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed developmental rodent models. Transl Psychiatry (2012) 1.00
Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain (2013) 1.00
The extended amygdala and the dopamine system: another piece of the dopamine puzzle. J Neuropsychiatry Clin Neurosci (2003) 1.00
Reinforcement learning and dopamine in schizophrenia: dimensions of symptoms or specific features of a disease group? Front Psychiatry (2013) 1.00
A linear model for estimation of neurotransmitter response profiles from dynamic PET data. Neuroimage (2011) 0.99
Pharmacology of hallucinations: several mechanisms for one single symptom? Biomed Res Int (2014) 0.99
A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia. Psychopharmacology (Berl) (2008) 0.99
Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology (2013) 0.99
Working memory contributions to reinforcement learning impairments in schizophrenia. J Neurosci (2014) 0.97
Developmental vitamin D deficiency alters dopamine-mediated behaviors and dopamine transporter function in adult female rats. Psychopharmacology (Berl) (2009) 0.96
Subcortical dopaminergic deficits in a DISC1 mutant model: a study in direct reference to human molecular brain imaging. Hum Mol Genet (2013) 0.95
Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice. Neuropharmacology (2010) 0.95
Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry (2012) 0.95
COMT Val158Met genotype selectively alters prefrontal [18F]fallypride displacement and subjective feelings of stress in response to a psychosocial stress challenge. PLoS One (2013) 0.93
Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl) (2006) 0.93
Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci (2002) 0.92
Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology (2010) 0.91
Animal models of schizophrenia: a critical review. J Psychiatry Neurosci (2001) 0.91
Prenatal inflammation-induced hypoferremia alters dopamine function in the adult offspring in rat: relevance for schizophrenia. PLoS One (2010) 0.90
Cholinergic connectivity: it's implications for psychiatric disorders. Front Cell Neurosci (2013) 0.89
Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl) (2004) 0.89
Dopamine receptor homooligomers and heterooligomers in schizophrenia. CNS Neurosci Ther (2010) 0.89
Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophr Res (2015) 0.88
Dopamine genes and schizophrenia: case closed or evidence pending? Schizophr Bull (2007) 0.88
Genetic influence on the working memory circuitry: behavior, structure, function and extensions to illness. Behav Brain Res (2011) 0.87
Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response. Synapse (2009) 0.87
Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci (2005) 0.87
Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Front Cell Neurosci (2013) 0.87
Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.86
From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. Curr Pharm Des (2012) 0.86
BDNF deficiency and young-adult methamphetamine induce sex-specific effects on prepulse inhibition regulation. Front Cell Neurosci (2013) 0.86
Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses. Neurotoxicology (2011) 0.86
MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant. J Biol Chem (2014) 0.85
Genetic variation associated with euphorigenic effects of d-amphetamine is associated with diminished risk for schizophrenia and attention deficit hyperactivity disorder. Proc Natl Acad Sci U S A (2014) 0.84
Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice. J Neural Transm (Vienna) (2011) 0.84
An Overview of the Association between Schizotypy and Dopamine. Front Psychiatry (2014) 0.84
Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol (2014) 0.84
Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl) (2008) 0.84
Pathway-Specific Dopamine Abnormalities in Schizophrenia. Biol Psychiatry (2016) 0.83
How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis. Trends Cogn Sci (2015) 0.83
Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response. Synapse (2011) 0.83
Brain connectivity studies in schizophrenia: unravelling the effects of antipsychotics. Curr Neuropharmacol (2012) 0.83
Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia. Schizophr Res (2013) 0.83
Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. Biol Psychiatry (2016) 0.83
Altered dopamine ontogeny in the developmentally vitamin D deficient rat and its relevance to schizophrenia. Front Cell Neurosci (2013) 0.82
Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol Psychiatry (2015) 0.82
Enhanced effect of dopaminergic stimulation on prepulse inhibition in mice deficient in the alpha subunit of G(z). Psychopharmacology (Berl) (2005) 0.82
Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study. Schizophr Bull (2014) 0.82
Prefronto-striatal physiology is associated with schizotypy and is modulated by a functional variant of DRD2. Front Behav Neurosci (2014) 0.82
Neonatal quinpirole treatment enhances locomotor activation and dopamine release in the nucleus accumbens core in response to amphetamine treatment in adulthood. Synapse (2010) 0.82
123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology (Berl) (2004) 0.82
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine. Neuropsychopharmacology (2016) 0.81
Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications. Front Neurosci (2016) 0.81
Cognition, dopamine and bioactive lipids in schizophrenia. Front Biosci (Schol Ed) (2011) 0.81
Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull (2014) 0.81
Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome. Schizophr Bull (2015) 0.81
Patients with schizophrenia show increased aversion to angry faces in an associative learning task. Psychol Med (2010) 0.81
Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients. Eur Arch Psychiatry Clin Neurosci (2011) 0.81
The development of a Clinician-Administered PTSD Scale. J Trauma Stress (1995) 22.71
The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry (1989) 16.61
Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med (1990) 16.54
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry (1989) 6.80
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry (1995) 5.34
Consistency of memory for combat-related traumatic events in veterans of Operation Desert Storm. Am J Psychiatry (1997) 5.13
Hippocampal volume reduction in major depression. Am J Psychiatry (2000) 5.04
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA (2000) 3.99
Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry (1990) 3.57
Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse--a preliminary report. Biol Psychiatry (1997) 3.39
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A (2000) 3.34
Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab (2001) 3.31
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A (1996) 3.28
The cellular neurobiology of depression. Nat Med (2001) 3.19
Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress (1998) 3.07
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry (2002) 3.01
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry (2000) 2.92
Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry (1993) 2.89
Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry (1999) 2.78
Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science (1999) 2.76
Neural correlates of exposure to traumatic pictures and sound in Vietnam combat veterans with and without posttraumatic stress disorder: a positron emission tomography study. Biol Psychiatry (1999) 2.62
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology (2011) 2.35
Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. Am J Psychiatry (1999) 2.35
Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. J Pharm Sci (1994) 2.31
Effects of early adverse experiences on brain structure and function: clinical implications. Biol Psychiatry (2000) 2.27
Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry (1999) 2.27
Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med (2000) 2.26
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry (1997) 2.22
Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry (1991) 2.17
Childhood physical abuse and combat-related posttraumatic stress disorder in Vietnam veterans. Am J Psychiatry (1993) 2.16
Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry (1994) 2.04
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry (1998) 2.03
Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry (2011) 2.03
Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry (1998) 2.02
Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry (1999) 1.97
X-linked spastic paraplegia and Pelizaeus-Merzbacher disease are allelic disorders at the proteolipid protein locus. Nat Genet (1994) 1.97
Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse (1996) 1.97
How does pindolol improve antidepressant action? Trends Pharmacol Sci (2001) 1.91
Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. Am J Psychiatry (1996) 1.87
Deficits in short-term memory in posttraumatic stress disorder. Am J Psychiatry (1993) 1.81
Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci U S A (1980) 1.78
Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nucl Med (1995) 1.77
Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions. J Cereb Blood Flow Metab (2000) 1.77
Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther (2009) 1.77
Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse (1996) 1.75
Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol (1995) 1.70
5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol (2000) 1.67
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry (1989) 1.66
COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry (2008) 1.63
Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry (1997) 1.59
Recurrent intracerebral hemorrhage. Neurology (1997) 1.59
Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry (2000) 1.58
No association between an allele at the D2 dopamine receptor gene (DRD2) and alcoholism. JAMA (1991) 1.56
Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry (1990) 1.56
Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab (2000) 1.56
Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. Am J Psychiatry (1993) 1.56
SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med (1995) 1.56
Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry (2000) 1.54
Hereditary factors in sleepwalking and night terrors. Br J Psychiatry (1980) 1.54
Dissociation and posttraumatic stress disorder in Vietnam combat veterans. Am J Psychiatry (1992) 1.52
Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology (1997) 1.50
Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects. J Nucl Med (1994) 1.49
Lithium treatment and serotoninergic function. Neuroendocrine and behavioral responses to intravenous tryptophan in affective disorder. Arch Gen Psychiatry (1989) 1.49
Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol Psychiatry (2000) 1.49
Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol (2001) 1.48
Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse (2001) 1.48
SPECT imaging of the benzodiazepine receptor: feasibility of in vivo potency measurements from stepwise displacement curves. J Nucl Med (1991) 1.47
Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. Arch Gen Psychiatry (1989) 1.47
A critical review of the contribution of eye movement recordings to the neuropsychology of obsessive compulsive disorder. Acta Psychiatr Scand (2011) 1.46